Skip to main content
. 2014 Feb 27;9(2):e89179. doi: 10.1371/journal.pone.0089179

Figure 4. BMP2 inhibition prevents the osteogenic effects of high phosphate.

Figure 4

A and B) Noggin administration (200 ng/ml) prevented the expression of osteogenic markers such as Osterix and Runx2 (a p<0.001 vs. high phosphate treated cells) and reduced calcium deposition. C) Alkaline phosphatase activity was not modified after Noggin administration. The figures are representative of at least three experiments.